PeptiDream Inc.

PeptiDream did not state a single consolidated revenue figure or EPS in the spoken transcript, but management said FY2026 revenue is forecast at JPY 32 billion plus an upfront payment, with JPY 15 billion of that tied to discovery business revenue assumptions. FY2026 R&D expense is expected to be JPY 6.4 billion, up from JPY 5 billion in FY2025, and Kaneshiro also referenced FY2025 total costs of JPY 23.5 billion. Cash at the end of December 2025 was JPY 28.6 billion, net cash positive was maintained, and management said equity financing is not planned. On pipeline guidance, Reid said 6 to 12 programs are expected to enter clinical development in 2026, which would leave 19 to 25 clinical programs by year-end; at the same time, management reiterated a long-term revenue goal of JPY 100 billion.

Patrick Reid framed FY2025 as the start of PeptiDream’s transition from a discovery company into a discovery-and-development company, driven by a deeper internal and partnered pipeline. He highlighted progress across five core therapeutic areas, especially radiopharmaceuticals, oral/injectable peptides, oligo delivery, cytotoxic conjugates, and multifunctional peptide conjugates, and said the first wholly owned CAXI program is set to enter U.S. Phase I soon. His tone was upbeat but more measured on monetization timing, emphasizing that future value should come from clinical progression and asset selection rather than near-term deal timing.

Kiyofumi Kaneshiro said FY2025 underperformed initial expectations mainly because the oral myostatin out-licensing deal did not close, while the radiopharmaceutical business continued to grow and stayed profitable for the fourth straight year after the 2022 merger. He cited JPY 28.6 billion in cash at end-December 2025, said net cash positive was maintained, and stressed that financial soundness remains important, so equity financing is not scheduled. For FY2026, he guided to JPY 32 billion plus upfront payments, broke discovery revenue into milestone/R&D funding plus roughly JPY 1 billion from new deals or expansion, and said R&D will rise to JPY 6.4 billion from JPY 5 billion as the company invests more in pipeline advancement and manufacturing readiness.

Analysts focused on the structure and credibility of FY2026 guidance, especially the JPY 15 billion discovery-business component and whether myostatin, IL-17, CAIX, and Claudin are included in upside. Management said the base forecast is deliberately conservative and that higher-value deals may slip depending on partner selection and data timing, with myostatin’s timing still uncertain because it must be matched with the right oral obesity partner. On capital allocation and growth, management said headcount rose to 810 from 761 mainly to prepare PDRadiopharma for manufacturing and sales expansion, and Reid explained the management reorganization is meant to build the strategy, operations, and portfolio-management talent needed as PeptiDream becomes more development-focused.